Cargando…

New treatment options for metastatic renal cell carcinoma

During the last decade, the treatment of advanced or metastatic renal cell carcinoma (RCC) was revolutionised with the advent of antiangiogenic drugs and tyrosine-kinase inhibitors. Several agents targeting the vascular endothelial growth factor (VEGF) pathway (sunitinib, bevacizumab, pazopanib, axi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Rodriguez-Vida, Alejo, Hutson, Thomas E, Bellmunt, Joaquim, Strijbos, Michiel H
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	ESMO Open 2017
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5519813/ https://www.ncbi.nlm.nih.gov/pubmed/28761748 http://dx.doi.org/10.1136/esmoopen-2017-000185

Ejemplares similares

Predictive and prognostic biomarkers of targeted agents and modern immunotherapy in renal cell carcinoma
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2016)

New treatment options for metastatic renal cell carcinoma with prior anti-angiogenesis therapy
por: Zarrabi, Kevin, et al.
Publicado: (2017)

New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib
por: Cowey, C Lance, et al.
Publicado: (2010)

Treatment Options in Metastatic Renal Cell Carcinoma: Focus on mTOR Inhibitors
por: Pal, Sumanta Kumar, et al.
Publicado: (2010)

Sequential Therapy in Metastatic Renal Cell Carcinoma
por: Hirsch, Bradford R., et al.
Publicado: (2016)

Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy
por: Mickisch, Gerald HJ, et al.
Publicado: (2011)

Atezolizumab in patients with renal insufficiency and mixed variant histology: analyses from an expanded access program in platinum-treated locally advanced or metastatic urothelial carcinoma
por: Hoffman-Censits, Jean, et al.
Publicado: (2020)

Cost-Effectiveness of the First Line Treatment Options For Metastatic Renal Cell Carcinoma in India
por: Gupta, Dharna, et al.
Publicado: (2023)

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015)

SEOM clinical guidelines for the treatment of renal cell carcinoma
por: Bellmunt, J., et al.
Publicado: (2014)

Current Options for Second-Line Systemic Therapy in Metastatic Renal Cell Carcinoma
por: Mitsogiannis, Iraklis C., et al.
Publicado: (2022)

New Treatment Options in Metastatic Pancreatic Cancer
por: Fudalej, Marta, et al.
Publicado: (2023)

Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis
por: Procopio, G, et al.
Publicado: (2013)

Pretubulysin: a new option for the treatment of metastatic cancer
por: Braig, S, et al.
Publicado: (2014)

Current Management Options in Metastatic Renal Cell Cancer
por: Gangadaran, Sittu Govindasamy Dinakaran
Publicado: (2017)

Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma
por: Hutson, T E, et al.
Publicado: (2014)

Prognostic factors for survival in 1059 patients treated with sunitinib for metastatic renal cell carcinoma
por: Motzer, R J, et al.
Publicado: (2013)

Metastatic penile carcinoma – an update on the current diagnosis and treatment options
por: Barski, Dimitri, et al.
Publicado: (2014)

Capecitabine in the treatment of metastatic renal cell carcinoma
por: Oevermann, K, et al.
Publicado: (2000)

Pazopanib as a possible option for the treatment of metastatic non-clear cell renal carcinoma patients: a systematic review
por: Bersanelli, Melissa, et al.
Publicado: (2020)

Change in Neutrophil-to-lymphocyte ratio (NLR) in response to immune checkpoint blockade for metastatic renal cell carcinoma
por: Lalani, Aly-Khan A., et al.
Publicado: (2018)

Treatment options for localised renal cell carcinoma of the transplanted kidney
por: Motta, Gloria, et al.
Publicado: (2020)

Radium-223 Chloride: A New Treatment Option for Metastatic Castration-Resistant Prostate Carcinoma
por: Pinto, Álvaro, et al.
Publicado: (2012)

Abiraterone: moving up in line?
por: Strijbos, Michiel
Publicado: (2018)

Circulating proteins as potential biomarkers of sunitinib and interferon-α efficacy in treatment-naïve patients with metastatic renal cell carcinoma
por: Harmon, Charles S., et al.
Publicado: (2013)

Identification of Tissue microRNAs Predictive of Sunitinib Activity in Patients with Metastatic Renal Cell Carcinoma
por: Prior, Celia, et al.
Publicado: (2014)

Contemporary Treatment of Metastatic Renal Cell Carcinoma
por: Stukalin, Igor, et al.
Publicado: (2016)

Update on the treatment of metastatic renal cell carcinoma
por: Medina López, Rafael Antonio, et al.
Publicado: (2022)

Treatment of Refractory Metastatic Renal Cell Carcinoma
por: Vento, Joseph A., et al.
Publicado: (2022)

Treatment Options for Metastatic Urothelial Carcinoma After First-Line Chemotherapy
por: Tassinari, Elisa, et al.
Publicado: (2022)

Immunotherapy and Metastatic Renal Cell Carcinoma: A Review of New Treatment Approaches
por: Kathuria-Prakash, Nikhita, et al.
Publicado: (2021)

Metastatic Renal Cell Carcinoma: The Importance of Immunohistochemistry in Differential Diagnosis
por: Custódio, Sandra, et al.
Publicado: (2012)

Immunotherapy: A new standard in the treatment of metastatic clear cell renal cell carcinoma
por: Popovic, Maja, et al.
Publicado: (2022)

Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck
por: Argiris, Athanassios, et al.
Publicado: (2017)

Urothelial carcinoma management in elderly or unfit patients()
por: Bellmunt, Joaquim, et al.
Publicado: (2016)

Metastatic Prostate Cancer—A Review of Current Treatment Options and Promising New Approaches
por: Posdzich, Philip, et al.
Publicado: (2023)

State-of-the-art treatment of metastatic renal cell carcinoma
por: Heng, D.Y.C., et al.
Publicado: (2009)

Review of guidelines on the treatment of metastatic renal cell carcinoma
por: Soulières, D.
Publicado: (2009)

A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC)
por: Molina, Ana M., et al.
Publicado: (2013)

Less invasive treatment option for renal carcinoma with venous tumor thrombus
por: Nagy, Zoltán, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_i0846s77jpof7kqcj6u59iuqm6